Piper Jaffray upgraded ISIS Pharmaceuticals (NASDAQ: ISIS) from Neutral to Overweight with a price target of $80.00 (from $64.00).Analyst Joshua ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE